What medication adjustments are recommended to improve insomnia and control excessive respiratory secretions in an elderly frail hospice patient with metastatic lung cancer who is on multiple opioids (hydromorphone oral and intravenous, fentanyl transdermal), ipratropium‑albuterol inhalation, oral atropine drops, dexamethasone, haloperidol, sertraline, and who has failed diazepam (Valium) for insomnia and has pruritus from a scopolamine patch used for secretions?

Medication Recommendations for Insomnia and Secretion Management in Hospice Patient with Metastatic Lung Cancer

Insomnia Management

Replace diazepam with lorazepam 0.5–1 mg orally at bedtime, or consider adding low-dose trazodone 25–50 mg at bedtime as first-line alternatives for refractory insomnia in this hospice patient. 1

Rationale for Changing Benzodiazepine Strategy

• Diazepam has a very long half-life and active metabolites that accumulate in frail elderly patients, potentially causing paradoxical agitation, confusion, and daytime sedation without improving nighttime sleep 1
• Lorazepam 0.5–1 mg orally at bedtime is specifically recommended by NCCN guidelines for insomnia in palliative care patients and has a shorter half-life with no active metabolites, making it more appropriate for elderly frail patients 1
• The current regimen already includes diazepam 5 mg at bedtime plus an additional PRN dose of 10 mg (2 tabs) every 6 hours for anxiety, which represents excessive benzodiazepine exposure that may be counterproductive 1

Alternative Non-Benzodiazepine Options

• Trazodone 25–100 mg orally at bedtime is the first-line pharmacologic option recommended by NCCN for insomnia in palliative care and has sedating properties without the dependence risks of benzodiazepines 1
• Mirtazapine 7.5–30 mg at bedtime is another NCCN-recommended option that provides both sedation and appetite stimulation, which may benefit this cachectic patient 1
• Olanzapine 2.5–5 mg at bedtime or quetiapine 25–50 mg at bedtime are additional options if the patient has concurrent delirium or agitation 1

Critical Considerations

• Avoid increasing benzodiazepine doses further, as tolerance develops rapidly and higher doses increase fall risk, respiratory depression (particularly concerning given the patient's lung cancer and dyspnea), and delirium in elderly hospice patients 1
• The patient is already on sertraline 100 mg daily for depression; adding trazodone is safe and may provide synergistic antidepressant effects at higher doses 1
• Sleep hygiene measures should be implemented concurrently, though pharmacologic intervention is appropriate given the terminal nature of the illness 1

---

Secretion Management

Switch from scopolamine patch to glycopyrrolate 0.2–0.4 mg IV or subcutaneously every 4 hours as needed for secretion control, as it does not cross the blood-brain barrier and will not cause pruritus or CNS side effects. 1, 2, 3

Why Glycopyrrolate is Superior

• Glycopyrrolate is the preferred first-line anticholinergic for managing excessive secretions because it does not cross the blood-brain barrier, making it significantly less likely to cause sedation, drowsiness, confusion, or delirium compared to scopolamine 1, 2, 3
• The quaternary ammonium structure of glycopyrrolate limits CNS penetration, eliminating the pruritus and cognitive side effects this patient is experiencing with scopolamine 3
• NCCN guidelines specifically recommend glycopyrrolate 0.2–0.4 mg IV or subcutaneously every 4 hours as needed for excessive secretions in palliative care 1, 2, 3
• Multiple studies demonstrate equivalent or superior efficacy of glycopyrrolate compared to scopolamine for reducing noisy respirations in dying patients, with better tolerability 4

Practical Administration

• Start with glycopyrrolate 0.2 mg subcutaneously every 4 hours as needed, then increase to 0.4 mg every 4 hours if secretions remain inadequately controlled 3
• Subcutaneous administration is preferred in hospice settings as it avoids the need for IV access and provides consistent absorption 4
• Discontinue the scopolamine patch immediately to eliminate the source of pruritus; note that transdermal scopolamine has a 12-hour onset time and is inappropriate for urgent symptom control anyway 1, 2

Alternative if Glycopyrrolate Unavailable

• Atropine 1% ophthalmic solution, 1–2 drops sublingually every 4 hours as needed, is a practical alternative if glycopyrrolate is not available 2, 5, 6
• The patient is already prescribed atropine 1% ophthalmic drops for secretions, so this formulation is on hand and can be used sublingually instead of the current ophthalmic route 6
• Sublingual atropine eyedrops have been shown effective for death rattle in terminal cancer patients and avoid the need for injections 6
• However, atropine does cross the blood-brain barrier more readily than glycopyrrolate and may cause some CNS effects, though less than scopolamine 5, 3

What NOT to Do

• Do not apply transdermal scopolamine patches to imminently dying patients or those needing urgent secretion control—the 12-hour onset makes them ineffective for acute symptom management 1, 2
• Do not use hyoscyamine as an alternative, as it penetrates the blood-brain barrier similarly to atropine and scopolamine, increasing delirium risk 5
• Avoid oral anticholinergics in this population, as dysphagia and altered consciousness make administration difficult and absorption unreliable 4

---

Additional Considerations for This Complex Patient

Opioid Optimization for Dyspnea

• The patient is on fentanyl 12 mcg/hr patch plus multiple PRN hydromorphone doses for pain, but opioids should also be optimized for dyspnea management given the lung cancer with metastases 1, 2
• For patients already on chronic opioids, increase the baseline opioid dose by 25% to manage dyspnea rather than relying solely on PRN dosing 1, 2
• Consider converting some of the PRN hydromorphone to scheduled dosing to provide more consistent dyspnea control 2

Benzodiazepine Role in Dyspnea

• Benzodiazepines should only be used as adjuncts to opioids for dyspnea, never as monotherapy, and are most appropriate when anxiety accompanies breathlessness 1, 2
• The current diazepam regimen may be contributing to sedation without effectively treating dyspnea; lorazepam 0.5–1 mg every 4 hours PRN would be more appropriate if benzodiazepines are needed for dyspnea-associated anxiety 2

Polypharmacy Concerns

• This patient is on 20 medications with significant overlap in sedating effects (fentanyl, hydromorphone, diazepam, haloperidol, sertraline, dexamethasone) 1
• Simplifying the regimen by eliminating ineffective medications (diazepam for insomnia, scopolamine patch for secretions) and consolidating to more effective alternatives will improve symptom control and reduce adverse effects 1
• The dexamethasone 4 mg daily may be contributing to insomnia and should be given in the morning rather than evening if not already scheduled that way 1